Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas

Expression of EGFR in high grade osteosarcomas has been observed to be correlated with an improved prognosis. Yet, the underlying mechanism remained unclear since amplifications of EGFR have rarely been described. Recently, the length of a polymorphic CA repeat located at a 5′‐regulatory sequence in the intron 1 of the EGFR gene (SSR I) has been shown to be associated with its basal transcriptional activity. We therefore determined the allelic length of CA SSR‐I in 219 cases of high grade osteosarcoma and correlated the results with EGFR expression in 34 cases, the presence of amplifications within the CA SSR‐I repeat in 59 cases, and clinical follow‐up. Our results confirm that in osteosarcoma patients short alleles are more frequent than longer ones, 16 CA repeats being the most frequent. The allele composition differed significantly from the one recently described in a healthy control population (P < 0.01). Short alleles tended to be associated with increased expression of EGFR. Amplifications of the EGFR gene were seen in 13.5% of cases. Significant correlations between allele length composition and neoadjuvant chemotherapy response or long term clinical outcome could not be established. While we were able to show that high frequency of EGFR expression in osteosarcomas is associated with predominantly short alleles of EGFR‐CA SSR I, persisting shortcomings in the correspondence with clinical data point toward the existence of additional, putatively more important transcription control mechanisms for EGFR in osteosarcomas which might account for the good prognostic value of EGFR expression. © 2008 Wiley‐Liss, Inc.

[1]  B. Brandt,et al.  Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response , 2006, Clinical Cancer Research.

[2]  S. Knuutila,et al.  Gene amplifications in osteosarcoma—CGH microarray analysis , 2005, Genes, chromosomes & cancer.

[3]  E. van Marck,et al.  Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. , 2002, European journal of cancer.

[4]  Manuel Hidalgo,et al.  An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors , 2004, Cancer Research.

[5]  C. Liedtke,et al.  Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression , 2006, Laboratory Investigation.

[6]  J. Isola,et al.  Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence—first results of an inter‐ethnic breast cancer study , 2004, The Journal of pathology.

[7]  W. Winkelmann,et al.  Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas , 2002, International journal of cancer.

[8]  S. Groshen,et al.  Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  S. Leenstra,et al.  Malignant astrocytoma‐derived region of common amplification in chromosomal band 17p12 is frequently amplified in high‐grade osteosarcomas , 1997, Genes, chromosomes & cancer.

[10]  Ge Zhang,et al.  Statistical power of association using the extreme discordant phenotype design , 2006, Pharmacogenetics and genomics.

[11]  K. Straif,et al.  Modification of Breast Cancer Risk in Young Women by a Polymorphic Sequence in the egfr Gene , 2004, Cancer Research.

[12]  K. Zänker,et al.  Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1* , 1999, The Journal of Biological Chemistry.

[13]  G. Delling,et al.  Morphological grades of regression in osteosarcoma after polychemotherapy — Study COSS 80 , 2004, Journal of Cancer Research and Clinical Oncology.

[14]  O. Kallioniemi,et al.  Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. , 2000, Cancer genetics and cytogenetics.

[15]  S. Groshen,et al.  Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. , 2005, Clinical colorectal cancer.

[16]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Simon,et al.  Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. , 2000, Cancer research.

[18]  S. Knuutila,et al.  Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. , 1995, Cancer research.

[19]  C. Liedtke,et al.  Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma , 2004, Laboratory Investigation.

[20]  P. V. van Diest,et al.  Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas , 2006, Journal of Clinical Pathology.

[21]  S. Groshen,et al.  Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab , 2006, Pharmacogenetics and genomics.

[22]  W. Winkelmann,et al.  Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome , 2007, Clinical Cancer Research.

[23]  S. Knuutila,et al.  Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. , 2002, Cancer genetics and cytogenetics.

[24]  S. Knuutila,et al.  Amplification of 17p11.2∼p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma , 2002 .

[25]  T. Giordano,et al.  Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma , 2004, Cancer Research.

[26]  M. Hidalgo,et al.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Bielack,et al.  Surgical expertise and outcome in osteosarcoma trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Radig,et al.  Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. , 1995, General & diagnostic pathology.

[29]  S. Bielack,et al.  Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.